title: Anisodamine restores bowel circulation in burn shock.
abstract: In a group of eight burn patients with a mean of 65.3 +/- 17.4 per cent TBSA burn injury (range 50-90 per cent TBSA), accompanied by a mean of 43.5 +/- 18.9 per cent TBSA full-thickness injury, it was shown that the evidence of global hypovolaemia had disappeared at 12 h after the injury following aggressive fluid resuscitation, while there was still a subnormal pHi of stomach at 48 h. As a prolonged period of inadequacy of oxygen delivery to the intestine might result in impairment of the intestinal mucosal barrier function, and then endogenous endotoxaemia might ensue, it seems to be important to correct intestinal hypoxia as early as possible. Since the inadequate perfusion to the gut wall is due to selective vasoconstriction of the mesenteric vasculature, logic dictates that the use of a vasodilator is in order. Anisodamine, an anticholinergic drug, was then given in six burn patients with comparable burn size and amount of fluid replenishment with the eight patients in the control group. It was clearly demonstrated that gastric pHi returned to normal before 48 h after injury. Plasma endotoxin and TNF contents were measured, and they were significantly lower than control values after 72 h. In conclusion, it is believed that anisodamine might be a valuable adjunct to the resuscitation regime of burn shock, and, therefore, a promising drug to abate endogenous endotoxaemia subsequent to splanchnic vasoconstriction due to hypovolaemia. The shortcomings of the drug were a mild abdominal distention and tachycardia after its administration.
authors.affiliation: Burn Center, 304th Hospital, Beijing, People's Republic of China.
authors.forename: C Y
authors.initials: CY
authors.lastname: Sheng
authors.forename: W Y
authors.initials: WY
authors.lastname: Gao
authors.forename: Z R
authors.initials: ZR
authors.lastname: Guo
authors.forename: L X
authors.initials: LX
authors.lastname: He
mesh_terms: D000328:Adult; D002056:Burns / Q000150:complications / Q000188:drug therapy*; D004731:Endotoxins / Q000032:analysis; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D006863:Hydrogen-Ion Concentration / Q000187:drug effects; D007275:Injections, Intravenous; D015601:Injury Severity Score; D008297:Male; D008875:Middle Aged; D015532:Rehydration Solutions / Q000008:administration & dosage; D012769:Shock / Q000150:complications / Q000188:drug therapy*; D012991:Solanaceous Alkaloids / Q000008:administration & dosage / Q000627:therapeutic use*; D013152:Splanchnic Circulation / Q000187:drug effects*; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000032:analysis / Q000187:drug effects; D014661:Vasoconstriction / Q000187:drug effects; D014665:Vasodilator Agents / Q000008:administration & dosage / Q000627:therapeutic use*
chemical_list: D004731:Endotoxins; D015532:Rehydration Solutions; D012991:Solanaceous Alkaloids; D014409:Tumor Necrosis Factor-alpha; D014665:Vasodilator Agents; C003922:anisodamine